A1 cancelled

in a concentration of at least about 250 mg/ml, wherein said variant is a polypeptide that has IGF-I activity and differs from the amino acid sequence for said human IGF-I by up to 10 amino acid residues.

Please cancel claim 2 without prejudice or disclaimer.

Please amend claim 3, as follows:

A2

2 ~~3~~. (amended) The [IGF-I] composition of claim [2]1, wherein said [syrup comprises]human IGF-I or variant thereof is present in a concentration of about 250 mg/ml to about 500 mg/ml.

Please amend claim 4, as follows:

A3

3 ~~4~~. (amended) The [IGF-I] composition of claim [2]1, wherein said [syrup comprises]human IGF-I or variant thereof is present in a concentration of about 350 mg/ml, and wherein said [syrup]composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

Please cancel claims 8 and 12 without prejudice or disclaimer.

Please amend claim 13, as follows:

A4

4 ~~13~~. (amended) A kit for reconstituting a pharmaceutical composition comprising biologically active human IGF-I or biologically active variant thereof, said kit comprising [a carrier being compartmentalized to receive in close confinement therein one or more container means, wherein one of said container means contains a highly concentrated form of biologically active IGF-I or variant thereof, wherein said IGF-I or variant thereof is present in a concentration of at least about 250 mg/ml,] the composition of claim 1 and [another of said container means contains] a pharmaceutically acceptable buffered solution having a pH less than or equal to about pH 5.0.

Please amend claim 16, as follows:

~~16.~~ (amended) A [composition prepared according to the method of claim 15, wherein said composition is a] pharmaceutical composition comprising the composition of claim 1.

~~19.~~ (amended) A [composition prepared according to the method of claim 15, wherein said composition is a ]cryogenically produced PLGA microsphere comprising the composition of claim 1.

~~20.~~ (amended) The microsphere of claim ~~19~~, wherein said microsphere comprises a lyophylized form of said [syrup]composition.

Please add the following new claims:

--~~28.~~ The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by up to 5 amino acid residues.

~~29.~~ The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by up to 2 amino acid residues.

~~30.~~ The composition of claim 1, wherein said variant differs from the amino acid sequence for said human IGF-I by 1 amino acid residue.

~~31.~~ The composition of claim 1, wherein said human IGF-I is recombinant human IGF-I.

~~32.~~ The composition of claim ~~31~~, wherein said recombinant human IGF-I is present at a concentration of about 250 mg/ml to about 500 mg/ml.

15 ~~38.~~ 13 The composition of claim ~~31~~, wherein said recombinant human IGF-I is present in a concentration of about 350 mg/ml, and wherein said composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

B7 Cont'd 16 ~~34.~~ A low salt-containing composition comprising biologically active human IGF-I in a concentration of at least about 250 mg/ml.

17 ~~35.~~ 16 The composition of claim ~~34~~, wherein said human IGF-I is recombinant human IGF-I.

18 ~~36.~~ 16 The composition of claim ~~34~~, wherein said human IGF-I is present in a concentration of about 250 mg/ml to about 500 mg/ml.

19 ~~37.~~ 16 The composition of claim ~~34~~, wherein said human IGF-I is present in a concentration of about 350 mg/ml, and wherein said composition has a density of about 1.07 g/ml and a viscosity of about 15,700 cps.

20 ~~38.~~ A pharmaceutical composition comprising the composition of claim 16 ~~34~~.

21 ~~39.~~ A cryogenically produced PLGA microsphere comprising the composition of claim 16 ~~34~~.

22 ~~40.~~ A pharmaceutical composition comprising the composition of claim 19 ~~37~~.

23 ~~41.~~ A cryogenically produced PLGA microsphere comprising the composition of claim 19 ~~37~~.